Metabolomics approach: Interpretation of changes in rat plasma metabolites after solifenacin treatment

被引:0
作者
Akman, Tugrul Cagri [1 ]
Kadioglu, Yucel [2 ]
Senol, Onur [2 ]
Erkayman, Beyzagul [3 ]
机构
[1] Erzincan Binali Yildirim Univ, Dept Analyt Chem, Fac Pharm, TR-24100 Erzincan, Turkey
[2] Ataturk Univ, Fac Pharm, Dept Analyt Chem, Erzurum, Turkey
[3] Ataturk Univ, Fac Pharm, Dept Pharmacol, Erzurum, Turkey
关键词
Solifenacin succinate; Metabolomics; Rat; LC-Q-TOF; MS; ANTIMUSCARINIC AGENT SOLIFENACIN; SMOOTH-MUSCLE-CELLS; OVERACTIVE BLADDER; DOUBLE-BLIND; CONTROLLED TRIAL; PROLIFERATION; RECEPTORS; EFFICACY; SAFETY;
D O I
10.1590/s2175-97902022e20849
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Changes in metabolite levels of patients using the long-term drug can be comprehensively demonstrated by pharmacometabolomic studies. In this study, biological alterations induced by the administration of solifenacin succinate were investigated with a pharmacometabolomics approach on rat metabolism. Plasma samples obtained from rats were analyzed by LC-Q-TOF/MS/MS. METLIN and HMDB databases were used to identify metabolites. Data were processed and classified with MATLAB 2017b. 53 m/z values were found to be significantly different between the drug and control groups (p ??? 0.01 and fold analysis > 1.5) and identified by comparing METLIN and HMDB databases. According to multivariate data analysis, changes in arachidonic acid, thromboxane A2, palmitic acid, choline, calcitriol, histamine phosphate, retinyl ester, l-cysteine, l-leucine, beta-alanine, l-histidine levels were found to be statistically significant compare to the control group. Differences in the biosynthesis of phenylalanine, aminoacyl-tRNA, tyrosine, tryptophan, metabolism of glycerophospholipid, cysteine, methionine, histidine, arachidonic metabolism have been successfully demonstrated by the metabolomics approach. Our study provides important information to explain the efficacy and toxicity of chronic administration of solifenacin succinate.
引用
收藏
页数:15
相关论文
共 39 条
  • [1] Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder
    Abrams, Paul
    Andersson, Karl-Erik
    Buccafusco, Jerry J.
    Chapple, Christopher
    de Groat, William Chet
    Fryer, Alison D.
    Kay, Gary
    Laties, Alan
    Nathanson, Neil M.
    Pasricha, Pankaj Jay
    Wein, Alan J.
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2006, 148 (05) : 565 - 578
  • [2] Qualitative Analysis of Factors Influencing Patient Persistence and Adherence to Prescribed Overactive Bladder Medication in UK Primary Care
    Ali, Mahmood
    Grogan, Sarah
    Powell, Sue
    Staniford, Leanne
    Nazir, Jameel
    Landeira, Margarita
    Covernton, Patrick J. O.
    Jaggi, Ashley
    Fatoye, Francis
    Holt, Maxine
    [J]. ADVANCES IN THERAPY, 2019, 36 (11) : 3110 - 3122
  • [3] Pharmacometabolomics analysis of plasma to phenotype clopidogrel high on treatment platelets reactivity in coronary artery disease patients
    Amin, Arwa M.
    Chin, Lim Sheau
    Teh, Chin-Hoe
    Mostafa, Hamza
    Noor, Dzul Azri Mohamed
    Kader, Muhamad Ali S. K. Abdul
    Hay, Yuen Kah
    Ibrahim, Baharudin
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 117 : 351 - 361
  • [4] Aragona P., 2013, Curr. Ophthalmol. Rep, V1, P58, DOI [10.1007/s40135-013-0011-7, DOI 10.1007/S40135-013-0011-7]
  • [5] Astellas Pharma U. Inc, 2009, TEL PACK INS
  • [6] Modern views on an ancient chemical: Serotonin effects on cell proliferation, maturation, and apoptosis
    Azmitia, EC
    [J]. BRAIN RESEARCH BULLETIN, 2001, 56 (05) : 413 - 424
  • [7] Basu M, 2019, GYNECOL OBSTET REPRO, V30, P1
  • [8] Patient-reported reasons for discontinuing overactive bladder medication
    Benner, Joshua S.
    Nichol, Michael B.
    Rovner, Eric S.
    Jumadilova, Zhanna
    Alvir, Jose
    Hussein, Mohamed
    Fanning, Kristina
    Trocio, Jeffrey N.
    Brubaker, Linda
    [J]. BJU INTERNATIONAL, 2010, 105 (09) : 1276 - 1282
  • [9] Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder
    Chapple, CR
    Rechberger, T
    Al-Shukri, S
    Meffan, P
    Everaert, K
    Huang, M
    Ridder, A
    [J]. BJU INTERNATIONAL, 2004, 93 (03) : 303 - 310
  • [10] Efficacy and Safety of Solifenacin Succinate 10 mg Once Daily: A Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial in Patients With Overactive Bladder
    Chu, Franklin
    Smith, Neila
    Uchida, Takeshi
    [J]. CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2009, 70 (06): : 405 - 420